JPRN-jRCT2071200100已完成1 期
Investigation of safety, tolerability and pharmacokinetic properties of single subcutaneous doses of NNC0194-0499 in Japanese and non-Asian male subjects(NN9500-4663)
Sudoh Yuki0 个研究点目标入组 42 人开始时间: 2021年2月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 55age old（—）
- 性别
- Male
入选标准
- •1. For Japanese subjects only, both parents of Japanese descent. For non-Asian subjects only, both parents of non-Asian descent.
- •2. Body mass index (BMI) between 23.0 and 34.9 kg/m2 (both inclusive). Overweight should be due to excess adipose tissue, as judged by the investigator.
- •3. Body weight >= 60 kg.
- •4. Considered by the investigator to be generally healthy based on the medical history, physical examination, and the results of vital signs, ECG, and clinical laboratory tests performed during the screening visit.
排除标准
- •Any disorder which in the opinion of investigator might jeopardise subject safety or compliance with the protocol.
研究者
相似试验
已完成
1 期
A research study of how a new medicine called amycretin, given as tablets, works in Japanese men with obesityObesityJPRN-jRCT2071230058Sudoh Yuki36
已完成
不适用
Investigation of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of NNC0480-0389 in combination with semaglutide s.c.diabetesNL-OMON55332ovo Nordisk156
招募中
不适用
A study to explore the safety, tolerability, pharmacokinetic profile, and potential efficacy of Guanabenz in patients with early childhood onset Vanishing White Matter (VWM)CACH1002929910012303NL-OMON55425Vrije Universiteit Medisch Centrum40
招募中
不适用
Guanabenz in VWMVanishing White Matter (VWM)Childhood ataxia with central nervous system hypomyelination (CACH)NL-OMON24121Amsterdam University Medical Centers, location VUmc, De Boelelaan 1117, 1081HV Amsterdam30
进行中（未招募）
1 期
Pediatric PK Study (POS IV and PFS)Prophylaxis of invasive fungal infections in immunocompromised pediatric subjects with neutropenia or expected neutropenia.EUCTR2014-002807-10-CZMerck Sharp & Dohme Corp.84